TT International Asset Management LTD cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 68.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,675 shares of the biopharmaceutical company's stock after selling 10,325 shares during the period. TT International Asset Management LTD's holdings in Gilead Sciences were worth $431,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in Gilead Sciences in the third quarter valued at approximately $25,000. Valued Wealth Advisors LLC raised its position in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the 2nd quarter worth $33,000. Cedar Wealth Management LLC grew its position in Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 160 shares during the last quarter. Finally, Friedenthal Financial acquired a new position in Gilead Sciences in the third quarter valued at $50,000. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Price Performance
Shares of GILD stock traded up $0.06 during mid-day trading on Monday, reaching $89.94. The stock had a trading volume of 6,521,645 shares, compared to its average volume of 6,113,990. The company has a market cap of $112.09 billion, a P/E ratio of 999.33, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The business has a 50-day simple moving average of $91.94 and a 200 day simple moving average of $83.39.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.29 earnings per share. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences's payout ratio is 3,422.22%.
Insiders Place Their Bets
In related news, CFO Andrew D. Dickinson sold 8,500 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the transaction, the chief financial officer now owns 132,373 shares of the company's stock, valued at approximately $12,173,021.08. This represents a 6.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company's stock, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 453,734 shares of company stock valued at $41,902,086. Corporate insiders own 0.16% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the stock. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an "outperform" rating and a $105.00 target price for the company. Maxim Group cut Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Citigroup started coverage on Gilead Sciences in a report on Thursday, November 14th. They issued a "buy" rating and a $125.00 target price on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Thursday, November 7th. Finally, Leerink Partnrs upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $97.96.
Get Our Latest Stock Analysis on GILD
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
